FIELD: biotechnology.
SUBSTANCE: invention represents an isolated antibody which binds to human TIM3, wherein said antibody comprises (a) a VH domain comprising (i) HVR-H1, comprising the amino acid sequence SEQ ID NO: 1, (ii) HVR-H2 comprising the amino acid sequence SEQ ID NO: 2, and (iii) HVR-H3 comprising an amino acid sequence selected from SEQ ID NO: 3, and (b) a VL domain comprising (i) HVR-L1 comprising the amino acid sequence SEQ ID NO: 12, (ii) HVR-L2 comprising the amino acid sequence SEQ ID NO: 5, and (iii) HVR-L3 comprising the amino acid sequence SEQ ID NO: 6.
EFFECT: invention provides higher clinical effectiveness in oncological diseases characterized by overexpression of TIM-3.
20 cl, 4 dwg, 16 tbl, 15 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATION THERAPY BASED ON T-CELL-ACTIVATING BISPECIFIC ANTIGEN-BINDING MOLECULES AGAINST CD3 AND FOLATE RECEPTOR 1 (FOLR1) AND ANTAGONISTS BINDING TO PD-1 AXIS | 2015 |
|
RU2753902C2 |
| ANTIBODIES AGAINST SIGNAL-REGULATORY ALPHA PROTEIN AND THEIR APPLICATION METHODS | 2017 |
|
RU2771964C2 |
| ANTIBODIES TO DENGUE VIRUS, POLYPEPTIDES CONTAINING FC-REGION OPTIONS AND THEIR APPLICATION METHODS | 2017 |
|
RU2758596C2 |
| ANTIBODIES TO DENGUE VIRUS WITH CROSS-REACTIVITY WITH ZIKA VIRUS | 2019 |
|
RU2811697C2 |
| ANTI-TAU PROTEIN ANTIBODIES AND METHODS OF USING SAID ANTIBODIES | 2016 |
|
RU2732122C2 |
| C5 ANTIBODIES AND THEIR APPLICATION METHODS | 2015 |
|
RU2746356C2 |
| BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO PD1 AND LAG3 | 2018 |
|
RU2778805C2 |
| ANTI-C5 ANTIBODIES AND METHODS FOR THEIR USE | 2017 |
|
RU2789788C2 |
| PD1 ANTIBODIES AND THEIR APPLICATION METHODS | 2016 |
|
RU2746409C1 |
| ANTIBODIES TO LAG3 | 2018 |
|
RU2778053C2 |
